


RealRate

PHARMACEUTICAL 2022

Eton Pharmaceuticals Inc. Rank 88 of 475









PHARMACEUTICAL 2022



RealRate

Eton Pharmaceuticals Inc. Rank 88 of 475

The relative strengths and weaknesses of Eton Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eton Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 428% points. The greatest weakness of Eton Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 104% points.

The company's Economic Capital Ratio, given in the ranking table, is 61%, being 338% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	23,604
Cost of Goods Sold	0
Intangible Assets	3,621
Liabilities, Current	4,558
Liabilities, Non-Current	15
Other Assets	125
Other Compr. Net Income	0
Other Expenses	2,623
Other Liabilities	5,262
Other Net Income	-460
Property and Equipment	115
Research and Development	6,235
Revenues	21,832
Selling, General and Administrative Expense	14,469

Output Variable	Value in 1000 USD
Assets	27,465
Liabilities	9,835
Expenses	23,327
Stockholders Equity	17,630
Net Income	-1,955
Comprehensive Net Income	-1,955
Economic Capital Ratio	61%

